Showing 1 - 20 results of 16,933 for search '(( three ((ad decrease) OR (a decrease)) ) OR ( i ((larger decrease) OR (marked decrease)) ))', query time: 0.67s Refine Results
  1. 1
  2. 2

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    S1 File - by Hongyu Li (1332669)

    Published 2025
    “…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”
  8. 8
  9. 9
  10. 10

    Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

    Published 2025
    “…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 49.6, <i>p</i> = 2.6 × 10<sup>−12</sup>, condition: intensity interaction F = 1.94, <i>p</i> = 0.02, nested ANOVA (mouse nested within session), F = 56.5, <i>p</i> = 8.8 × 10<sup>−14</sup>, condition: intensity interaction F = 3.5, <i>p</i> = 3.5 × 10<sup>−05</sup>). …”
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

    Published 2025
    “…The following labelling information is also included in the file: animal ID, group ID (i.e. 2=WT, 1=AD, 3=ATH or MIX), sex (1=male, 2=female), session ID (corresponding to the experimental imaging day), and trial ID (corresponding to the order of detected locomotion events within each experimental imaging session). …”
  16. 16

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…”
  17. 17

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…”
  18. 18
  19. 19
  20. 20

    Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”